Kamil Ali-Jackson, chief legal officer (CLO), chief compliance officer and corporate secretary with Nasdaq-listed Aclaris Therapeutics, has announced her retirement, effective January 3, 2022, from the company she co-founded in 2012.
Ali-Jackson has worked for more than 35 years in the legal and pharmaceutical industries. In addition to Aclaris, she co-founded NeXeption, a biopharmaceutical assets management company, and its affiliated companies, and served as its CLO from 2012 to 2020. Previously, she was legal counsel and a licensing business executive for a number of pharmaceutical companies such as Merck & Co, Dr Reddy’s Laboratories and Endo Pharmaceuticals.
Wayne, Pennsylvania-based Aclaris is a clinical-stage biopharmaceutical company developing drug candidates to address the needs of patients with immuno-inflammatory diseases.
Neal Walker, co-founder, president, CEO and director, says in a statement: ‘[O]n behalf of the entire Aclaris team and our board of directors, I thank Kamil for her hard work and dedication to the company. During her tenure, Kamil has been responsible for building and overseeing Aclaris’ legal, compliance, corporate communications, human resources and quality functions, and her significant contributions have contributed to the success of the company. We wish Kamil the very best in her retirement.’
Â
Ben Maiden
Ben Maiden is the editor-at-large of Governance Intelligence, an IR Media publication, having joined the company in December 2016. He is based in New York. Ben was previously managing editor of Compliance Reporter, covering regulatory and compliance...
